This post is part of a series featuring bargain stocks that are worth a look now. See more Cheap Stocks.
You've probably heard that heart disease is one of the leading causes of death in the U.S. I don't mean to be a total downer in bringing up this bit of trivia; in fact, the prevalence of cardiac-related illnesses is actually a boon for Minnesota-based St. Jude Medical (NYSE: STJ). The company is engaged in the design, manufacture, and distribution of various cardiovascular medical devices, including pacemakers, replacement valves, and many more.
In mid-October, St. Jude reported higher-than-expected third-quarter sales. The medical-device firm also tightened up its full-year outlook, primarily due to the effects of currency fluctuations. However, Chief Financial Officer John Heinmiller said STJ is "confident" it can meet or exceed Wall Street's 2009 earnings estimates.
St. Jude also believes it's well-insulated from macroeconomic turmoil. CEO Daniel Starks observed that his company's products address "key health concerns," which means they're hardly discretionary items. "We expect very minimal impact from the broader and economic dynamics, and think we're in a good defensive position that way," Stark noted.
There could be more downside for STJ from its current perch, but look for support to emerge from the stock's 160-month moving average. This long-term trendline contained the equity's pullbacks in 1998 and 2000, which means that St. Jude could catch a lift here once again. This moving average is currently rising through the $23 region.
Despite STJ's assurances about its solid fundamental position, no one seems too convinced on Wall Street. During the last two weeks of November, option traders on the International Securities Exchange (ISE) purchased nearly three puts for every call on the stock. Additionally, analysts have warned of rocky times ahead. In the month following its earnings report, STJ was hit with four price target cuts, a downgrade from S&P Equity, and a skeptical Hold initiation from Jefferies & Co.
Overall, it looks like expectations are quite low for St. Jude in the year ahead. The stock could capitalize on the Street's lukewarm attitude by maintaining its cautious approach to guidance, which allows for upside surprises in even the harshest of environments. In the meantime, look for the shares to regain their pulse after meeting up with their 160-month moving average, which could draw some skeptics off the sidelines.
Meanwhile, the shares are trading at a deep discount to their average five-year price/earnings ratio of 34.6. As of November 30, STJ's p/e ratio was a slim 14.02.
Elizabeth Harrow is an analyst and financial writer in the research department at Schaeffer's Investment Research. She is featured in the video series Schaeffer's Daily Q&A on SchaeffersResearch.com.











Reader Comments (Page 1 of 1)
12-25-2008 @ 9:54AM
charles said...
I would like to buy stock while everything is down but I do not know how to buy. How much is it going to cost per unit, from the cheap stocks that you have listed. Please help